The combined entity will enable us to better serve the needs of patients, healthcare professionals and our customers around the world
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
A significant proportion of healthcare professionals still tend to favor branded drugs
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
This acquisition enables MTD to open new, strategic markets
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Subscribe To Our Newsletter & Stay Updated